265 related articles for article (PubMed ID: 37176536)
1. Challenges of Treating ADHD with Comorbid Substance Use Disorder: Considerations for the Clinician.
Barbuti M; Maiello M; Spera V; Pallucchini A; Brancati GE; Maremmani AGI; Perugi G; Maremmani I
J Clin Med; 2023 Apr; 12(9):. PubMed ID: 37176536
[TBL] [Abstract][Full Text] [Related]
2. A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders.
Kollins SH
Curr Med Res Opin; 2008 May; 24(5):1345-57. PubMed ID: 18384709
[TBL] [Abstract][Full Text] [Related]
3. Managing attention-deficit/hyperactivity disorder in the presence of substance use disorder.
Upadhyaya HP
J Clin Psychiatry; 2007; 68 Suppl 11():23-30. PubMed ID: 18307378
[TBL] [Abstract][Full Text] [Related]
4. Comorbid attention deficit/hyperactivity disorder and substance use disorder: treatment considerations.
Klassen LJ; Bilkey TS; Katzman MA; Chokka P
Curr Drug Abuse Rev; 2012 Sep; 5(3):190-8. PubMed ID: 22571450
[TBL] [Abstract][Full Text] [Related]
5. Substance use disorders in children and adolescents with attention-deficit/hyperactivity disorder: implications for treatment and the role of the primary care physician.
Upadhyaya HP
Prim Care Companion J Clin Psychiatry; 2008; 10(3):211-21. PubMed ID: 18615170
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapeutic strategies for the treatment of attention-deficit hyperactivity (ADHD) disorder with comorbid substance-use disorder (SUD).
Perugi G; Pallucchini A; Rizzato S; De Rossi P; Sani G; Maremmani AG; Pinzone V; Maremmani I
Expert Opin Pharmacother; 2019 Feb; 20(3):343-355. PubMed ID: 30513231
[TBL] [Abstract][Full Text] [Related]
7. [International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder].
Özgen H; Spijkerman R; Noack M; Holtmann M; Schellekens ASA; van de Glind G; Banaschewski T; Barta C; Begeman A; Casas M; Crunelle CL; Daigre Blanco C; Dalsgaard S; Demetrovics Z; den Boer J; Dom G; Eapen V; Faraone SV; Franck J; González RA; Grau-López L; Groenman AP; Hemphälä M; Icick R; Johnson B; Kaess M; Kapitány-Fövény M; Kasinathan JG; Kaye SS; Kiefer F; Konstenius M; Levin FR; Luderer M; Martinotti G; Matthys FIA; Meszaros G; Moggi F; Munasur-Naidoo AP; Post M; Rabinovitz S; Ramos-Quiroga JA; Sala R; Shafi A; Slobodin O; Staal WG; Thomasius R; Truter I; van Kernebeek MW; Velez-Pastrana MC; Vollstädt-Klein S; Vorspan F; Young JT; Yule A; van den Brink W; Hendriks V
Z Kinder Jugendpsychiatr Psychother; 2021 Jan; 50(1):54-67. PubMed ID: 34397296
[TBL] [Abstract][Full Text] [Related]
8. Substance abuse in patients with attention-deficit hyperactivity disorder : therapeutic implications.
Schubiner H
CNS Drugs; 2005; 19(8):643-55. PubMed ID: 16097847
[TBL] [Abstract][Full Text] [Related]
9. Attention Deficit/Hyperactivity Disorder and Global Severity Profiles in Treatment-Seeking Patients with Substance Use Disorders.
Icick R; Moggi F; Slobodin O; Dom G; Mathys F; van den Brink W; Levin FR; Blankers M; Kaye S; Demetrovics Z; van de Glind G; Velez-Pastrana MC; Schellekens ASA;
Eur Addict Res; 2020; 26(4-5):201-210. PubMed ID: 32570249
[TBL] [Abstract][Full Text] [Related]
10. Clinical practice guideline on pharmacological and psychological management of adult patients with attention deficit and hyperactivity disorder and comorbid substance use.
Cunill R; Castells X; González-Pinto A; Arrojo M; Bernardo M; Sáiz PA; Flórez G; Torrens M; Tirado-Muñoz J; Fonseca F; Arranz B; Garriga M; Goikolea JM; Zorrilla I; Becoña E; López A; San L
Adicciones; 2022 Apr; 34(2):168-178. PubMed ID: 34171106
[TBL] [Abstract][Full Text] [Related]
11. Treatments for Adolescents With Comorbid ADHD and Substance Use Disorder: A Systematic Review.
Zaso MJ; Park A; Antshel KM
J Atten Disord; 2020 Jul; 24(9):1215-1226. PubMed ID: 25655767
[No Abstract] [Full Text] [Related]
12. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
Garnock-Jones KP; Keating GM
Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
[TBL] [Abstract][Full Text] [Related]
13. International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder.
Özgen H; Spijkerman R; Noack M; Holtmann M; Schellekens ASA; van de Glind G; Banaschewski T; Barta C; Begeman A; Casas M; Crunelle CL; Daigre Blanco C; Dalsgaard S; Demetrovics Z; den Boer J; Dom G; Eapen V; Faraone SV; Franck J; González RA; Grau-López L; Groenman AP; Hemphälä M; Icick R; Johnson B; Kaess M; Kapitány-Fövény M; Kasinathan JG; Kaye SS; Kiefer F; Konstenius M; Levin FR; Luderer M; Martinotti G; Matthys FIA; Meszaros G; Moggi F; Munasur-Naidoo AP; Post M; Rabinovitz S; Ramos-Quiroga JA; Sala R; Shafi A; Slobodin O; Staal WG; Thomasius R; Truter I; van Kernebeek MW; Velez-Pastrana MC; Vollstädt-Klein S; Vorspan F; Young JT; Yule A; van den Brink W; Hendriks V
Eur Addict Res; 2020; 26(4-5):223-232. PubMed ID: 32634814
[TBL] [Abstract][Full Text] [Related]
14. Irish adolescents with ADHD and comorbid substance use disorder.
Edokpolo O; Nkire N; Smyth BP
Ir J Psychol Med; 2010 Sep; 27(3):148-151. PubMed ID: 30282206
[TBL] [Abstract][Full Text] [Related]
15. The use of stimulants and atomoxetine in adults with comorbid ADHD and bipolar disorder.
Perugi G; Vannucchi G
Expert Opin Pharmacother; 2015; 16(14):2193-204. PubMed ID: 26364896
[TBL] [Abstract][Full Text] [Related]
16. Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication.
Molina BS; Hinshaw SP; Eugene Arnold L; Swanson JM; Pelham WE; Hechtman L; Hoza B; Epstein JN; Wigal T; Abikoff HB; Greenhill LL; Jensen PS; Wells KC; Vitiello B; Gibbons RD; Howard A; Houck PR; Hur K; Lu B; Marcus S;
J Am Acad Child Adolesc Psychiatry; 2013 Mar; 52(3):250-63. PubMed ID: 23452682
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults.
Santosh PJ; Sattar S; Canagaratnam M
CNS Drugs; 2011 Sep; 25(9):737-63. PubMed ID: 21870887
[TBL] [Abstract][Full Text] [Related]
18. Comorbid attention deficit hyperactivity disorder and substance use disorder complexity and chronicity in treatment-seeking adults.
Young JT; Carruthers S; Kaye S; Allsop S; Gilsenan J; Degenhardt L; van de Glind G; van den Brink W; Preen D
Drug Alcohol Rev; 2015 Nov; 34(6):683-93. PubMed ID: 25790353
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Dilemma of Differentiating Attention-Deficit/Hyperactivity Disorder (ADHD) From Mood Disorders and Other Common Psychiatric Illnesses in Substance Use Patient Population.
Muhammad N; Murugesan BG; Singal P; Antai A; Jain L
Cureus; 2023 Apr; 15(4):e37372. PubMed ID: 37041853
[TBL] [Abstract][Full Text] [Related]
20. The potential for misuse and abuse of medications in ADHD: a review.
Clemow DB; Walker DJ
Postgrad Med; 2014 Sep; 126(5):64-81. PubMed ID: 25295651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
